Denali Therapeutics’ Post

Come see me tomorrow and learn more about HemoCue’s rapid and lab-quality POC testing!

Comprehensive Motion Management on Unity. The future is here.

Please join us for this webinar! Cardiac and Vascular Safety Liabilities Using Totality of Evidence Approach

QurAlis presents! Emma Bowden, PhD, QurAlis' head of development, recently presented an overview of our Phase 1 ANQUR clinical trial - the first-ever study to evaluate a therapy that rescues #STATHMIN-2 (#STMN2) in #ALS - at the 3rd ALS Drug Development Summit. ANQUR is evaluating QRL-201, a first-in-class STMN2 #precisionmedicine for ALS that rescues STMN2 expression in ALS patients and could halt disease progression. QurAlis is exploring the use of the Unlearn.AI Digital Twin Generators in ANQUR. #neurodegenerativediseases

Tomorrow marks the beginning of an epic 4-day journey at the Convergence of Laboratory Medicine & In Vitro Diagnostics 2024, featuring the #CACLP & #CISCE tradeshows and 100 activities. 🎉🚀 Dive in and chart your course below 👇🏻 #IVD #diagnostics #laboratorymedicine #China #Chongqing #agenda #schedule #countdown

New Article by Cort Johnson, ‘Looking Back at 2023 in ME/CFS, Long COVID and FM- the Most, Best, Cleverest and Strangest,’ has highlighted two remarkable OMF initiatives. 🌍 OMF’s StudyME project, a global participant registry connecting those interested in participating in research studies with the researchers conducting them, has been named the ‘Cleverest Idea.’ 💊 The Life Improvement Trial (LIFT), a double-blind placebo trial that will investigate two drugs: Pyridostigmine (commonly known as Mestinon) and low-dose naltrexone (LDN) separately and together as a combination, has been recognized as the ‘Best New ME/CFS Clinical Trial.’ Read the full article here 👉 https://ow.ly/t3Os50QnBRe.

View the role of molecular characteristics in guiding treatment selection and clinical trial enrollment | 0.5-hour CME/CE | Video Activity #2 of 3 in the LGSOC Library #PRIME #CME #MedEd #ovariancancer https://bit.ly/3D7w79Z

As I reflect on the updates presented at The EBMT-European Hematology Association (EHA) 6th European CAR-T meeting, it is evident that we’ve only begun to scratch the surface of what’s possible with CAR (T) therapies.   My highlights: 💡 Our increasing understanding of the mechanisms of-CAR-T treatment toxicities, and the improved prophylactic and treatment strategies being utilised to manage these 💡 The progress being made with next-generation CAR-Ts using approaches such as genome editing, and the enormous potential they will bring 💡 The ever-expanding utility of CAR-T therapies, not only in haematological malignancies and solid tumours, but in a variety of other therapeutic areas – with particularly exciting advances being made in autoimmune diseases, and senescence & cellular regeneration Want to hear directly from the speakers on some these hot topics? Head to our event page https://lnkd.in/eGC94E-Q to find out more!   #CARTtherapy #CART24 #EBMT #EHA #vjhemonc